AR062726A1 - Composiciones que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
AR062726A1
AR062726A1 ARP070103993A ARP070103993A AR062726A1 AR 062726 A1 AR062726 A1 AR 062726A1 AR P070103993 A ARP070103993 A AR P070103993A AR P070103993 A ARP070103993 A AR P070103993A AR 062726 A1 AR062726 A1 AR 062726A1
Authority
AR
Argentina
Prior art keywords
anion
heteroaryl
aryl
alkyl
group
Prior art date
Application number
ARP070103993A
Other languages
English (en)
Inventor
Detief Sulzle
Thomas Brumby
Lutz Lehmann
Timo Stellfeld
Ananth Srinivasan
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR062726A1 publication Critical patent/AR062726A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Uso de tales compuestos como agentes de diagnostico por imágenes. Reivindicacion 1: Un compuesto caracterizado porque es de la formula química general (1) en donde G se selecciona entre el grupo que comprende -Cl, -Br, -I, -NO, -NO2, -NR4COCF3, - NR4SO2CF3, -N(R4)SO2R5, -N(CF3)2, -NHCSNHR4, -N(SO2R5)2 , -N(O)=NCONH2, -NR4CN, -NHCSR5, -N:::C, -N=C(CF3)2, -N=NCF3, -N=NCN, -NR4COR4, -NR4COOR5, -OSO2CF3 -OSO2C6H5, -OCOR5, -ONO2, -OSO2R5, -O-C=CH2, -OCF2CF3, -OCOCF3, -OCN, -OCF3, -C:::N, - C(NO2)3, -COOR4, -CONR4R5, -C(S)NH2, -CH=NOR4, -CH2SO2R4, -COCF3, -CF3, -CF2Cl-CBr3, -CClF2, -CCl3, -CF2CF3, -C:::CR4, -CH=NSO2CF3, -CH2CF3, -COR5, -CH=NOR5, -CH2CONH2, -CSNHR5, -CH=NNHCSNH2, -CH=NNHCONHNH2, -C:::C-CF3, -CF=CFCF3, -CF2-CF2-CF3, - CR4(CN)2, -COCF2CF2CF3, -C(CF3)3, -C(CN)3,CR4=C(CN)2, -1-pirrilo, -C(CN)=C(CN)2, -C-piridilo, -COC6H5, -COOC6H5, -SOCF3, -SO2CF3, -SCF3, -SO2CN, -SCOCF3, -SOR5, -S(OR5), -SC:::CR4, -SO2R5, -SSO2R5, -SR5, -SSR4, -SO2CF2CF3, -SCF2CF3, -S(CF3)=NSO2CF3, -SO2C6H5, -SO2N(R5)2, -SO2C(CF3)3, -SC(CF3)3, -SO(CF3)=NSO2CF3, -S(O)(=NH)CF3, -S(O)(=NH)R5, -S-C=CH2, -SCOR5, -SOC6H5, -P(O)C3F7, -PO(OR5)2, -PO(N(R5)2)2, -P(N(R5)2)2, -P(O)R52, y -PO(OR5)2 u otro grupo aceptor de electrones en donde el sustituyente respectivo puede estar en posicion orto, para o meta con respecto al grupo K, Q es hidrogeno, alquilo inferior ramificado o no ramificado, arilo, heteroarilo, -O-(alquilo C1-4), -CN, - halogeno, -SO2-R4, -NO2 o un arilo condensado o heteroarilo condensado en donde el sustituyente respectivo puede estar en posicion orto, para o meta con respecto al grupo K, en donde R4 es hidrogeno o alquilo inferior ramificado o no ramificado y R5 es alquilo inferior ramificado o no ramificado, L es un enlace, -CO-, SO2, -(CH2)d-CO-, -SO-, -C:::C-CO-, -[CH2]m-E-[CH2]n-CO-, -[CH2]m-E-[CH2]n-SO2, -C(=O)-O-, -NR10-, -O-, -(S)p-, -C(=O)NR12-, -C(=S)NR12-, -C(=S)O-, cicloalquilo C1-6, alquenilo, heterocicloalquilo, arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido, aralquilo, heteroaralquilo, alquiloxi, ariloxi, aralquiloxi, -SO2NR13-, -NR13SO2-, -NR13C (=O)O-, -NR13C(=O)NR12-, -NH-NH- y -NH-O-, en donde d es un entero entre 1 y 6, m y n, en forma independiente, son cualquier entero entre 0 y 5, E es un enlace, -S-, -O- o -NR9-, en donde R9 es H, alquilo C1-10, arilo, heteroarilo o aralquilo, p es cualquier entero entre 1 y 3, R10 y R12, en forma independiente, se seleccionan del grupo que comprende H, alquilo C1-10, arilo, heteroarilo o aralquilo y R13 H, alquilo C1-6, arilo, cicloalquilo, heterocicloalquilo, heteroarilo, aralquilo o heteroaralquilo sustituido o no sustituido, de cadena lineal o ramificada, Y es un enlace o un espaciador, U es un agente direccionador, X es CF3S(O)2O-, C4F9S(O)2O-, anion yoduro, anion bromuro, anion cloruro, anion perclorato (ClO4-), anion fosfato, anion trifluoroacetato (CF3-C(O)O-), o el anion de otra sal de un ácido inorgánico u orgánico, K es N+(R1) (R2) (R3) X- o W, en donde R1, R2 y R3 se seleccionan en forma independiente entre sí entre el grupo que comprende alquilo y aralquilo sustituido o insustituido, W es un isotopo de fluor, y una sal aceptable para uso farmacéutico de un ácido inorgánico u orgánico del mismo, un hidrato, complejo, éster, amida, solvato y prodroga del mismo.
ARP070103993A 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados AR062726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
AR062726A1 true AR062726A1 (es) 2008-11-26

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103993A AR062726A1 (es) 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (es)
EP (5) EP3056509A1 (es)
JP (2) JP5603074B2 (es)
KR (1) KR20090058553A (es)
AR (1) AR062726A1 (es)
AU (1) AU2007294124A1 (es)
BR (1) BRPI0716554A2 (es)
CA (2) CA2662449A1 (es)
CL (1) CL2007002620A1 (es)
CO (1) CO6150196A2 (es)
CR (1) CR10654A (es)
IL (4) IL197363A0 (es)
MA (1) MA30780B1 (es)
MX (1) MX2009002492A (es)
NO (1) NO20091428L (es)
PE (1) PE20080850A1 (es)
RU (1) RU2009112716A (es)
TN (1) TN2009000063A1 (es)
TW (1) TW200829277A (es)
WO (1) WO2008028688A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents
EP2146753A2 (en) * 2007-03-01 2010-01-27 Bayer Schering Pharma Aktiengesellschaft 18f fluoro-benzoyl labelled biological active compounds as diagnostic imaging agents as well as benzotriazol-1-yloxy-benzoyl , 2,5-dioxo-pyrrolidin-1-yloxy)benzoyl and trimethylammonio-benzoyl precursers thereof
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
CN105308056B (zh) * 2013-03-15 2018-03-20 癌靶技术有限责任公司 18f‑标记的靶向psma的pet成像剂
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3582771A4 (en) * 2017-02-17 2020-12-30 Yale University RADIOACTIVELY LABELED MEDICINAL PRODUCTS AND THE METHOD OF MANUFACTURING AND USING THEREOF
US20200131555A1 (en) 2017-07-11 2020-04-30 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
EP3661955A4 (en) 2017-08-03 2021-05-26 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CA3097568A1 (en) * 2018-04-20 2019-10-24 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
WO2022246118A2 (en) * 2021-05-20 2022-11-24 The Regents Of The University Of California Pet imaging tracers

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
HU208439B (en) * 1988-10-14 1993-10-28 Univ Tulane Process for producing pharmaceutical peptides
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
KR20010033595A (ko) 1997-12-24 2001-04-25 버텍스 파마슈티칼스 인코포레이티드 아스파틸 프로테아제 억제제의 전구약물
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU5414000A (en) * 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
AU2002228725A1 (en) * 2000-11-30 2002-06-11 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
AU2003218337A1 (en) 2002-04-09 2003-10-27 Eli Lilly And Company Growth hormone secretagogues
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
WO2004073650A2 (en) * 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
EP1912634A4 (en) 2005-07-29 2010-06-09 Bayer Healthcare Llc PREPARATION AND USE OF BIPHENYL AMINOACIDAL DERIVATIVES TO TREAT OBESITY
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents

Also Published As

Publication number Publication date
TN2009000063A1 (en) 2010-08-19
EP2455105A3 (en) 2012-09-05
EP2289564A3 (en) 2012-11-14
EP2455105B1 (en) 2016-02-17
US20080292548A1 (en) 2008-11-27
AU2007294124A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
EP2279759A3 (en) 2013-04-17
EP2063918A2 (en) 2009-06-03
EP2279759A2 (en) 2011-02-02
TW200829277A (en) 2008-07-16
IL211033A0 (en) 2011-04-28
JP5722966B2 (ja) 2015-05-27
JP2014028813A (ja) 2014-02-13
NO20091428L (no) 2009-06-03
US8557776B2 (en) 2013-10-15
WO2008028688A2 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
IL211526A0 (en) 2011-05-31
IL211527A0 (en) 2011-05-31
WO2008028688A3 (en) 2008-11-13
BRPI0716554A2 (pt) 2013-09-24
IL197363A0 (en) 2011-08-01
EP2063918B1 (en) 2014-02-26
KR20090058553A (ko) 2009-06-09
CO6150196A2 (es) 2010-04-20
JP2010503618A (ja) 2010-02-04
CL2007002620A1 (es) 2008-05-30
CA2858907A1 (en) 2008-03-13
CR10654A (es) 2009-04-14
EP2455105A2 (en) 2012-05-23
PE20080850A1 (es) 2008-09-02
JP5603074B2 (ja) 2014-10-08
MA30780B1 (fr) 2009-10-01
CA2662449A1 (en) 2008-03-13
RU2009112716A (ru) 2010-10-20
EP2289564A2 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
AR062726A1 (es) Composiciones que comprenden compuestos marcados con 18f y metodos relacionados
CO6220836A2 (es) Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo
Kang et al. Copper-catalyzed trifluoromethylthiolation of aryl and vinyl boronic acids with a shelf-stable electrophilic trifluoromethylthiolating reagent
Wang et al. Chloride ion-catalyzed generation of difluorocarbene for efficient preparation of gem-difluorinated cyclopropenes and cyclopropanes
ES2785034T3 (es) Métodos para el tratamiento de infecciones de virus de filoviridae
JP2012522873A5 (es)
IL264541A (en) History of sulfamolepyrolamide and their use as drugs for the treatment of jaundice b
BR102013003576A2 (pt) Métodos de produzir compostos de sulfilimina
RU2580915C2 (ru) Пламегасящая композиция, содержащая органическую кислоту
Liu et al. Efficient synthesis of unsymmetrical S-(bromodifluoromethyl) diarylsulfonium salts for electrophilic bromodifluoromethylating reagents
AR049401A1 (es) Aza-biciclononanos
ES2543588T3 (es) Derivados de 2-(2-hidroxibifenil-3-il)-1H-benzoimidazol-5-carboxamidina como inhibidores del factor VIIa
AR074705A1 (es) Procedimiento de preparacion de benzociclobutenos funcionalizados, intermediarios y aplicacion en la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
RU2011150488A (ru) Фосфорсодержащие антипирены
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
AR087683A1 (es) N-[1-((6-cloropiridin-3-il)metil)piridin-2-(1h)-ilideno]-2,2,2-trifluoroacetamida, metodo para su preparacion y un intermediario para su sintesis
Yanachkov et al. P 1, P 2-Diimidazolyl derivatives of pyrophosphate and bis-phosphonates–synthesis, properties, and use in preparation of dinucleoside tetraphosphates and analogs
RU2008153041A (ru) Производные фторалкоксикомбретастатина, способы их производства и использования
AR071592A1 (es) Fenoxibenzamidas sustituidas
HRP20211154T1 (hr) Postupak za pripravu derivata benzil-benzena supstituiranih glukopiranozilom
CN102336403A (zh) 一种高阻燃性可膨胀石墨的制备方法
PE20090956A1 (es) PROCESO PARA LA OBTENCION DE DERIVADOS DE PIRIDO [2,1-a] - ISOQUINOLINA
CN102408285B (zh) 一种甲苯衍生物的苄基碳氢直接胺化方法
Nurminen et al. Mechanisms of the substitution reactions of phosphoramidites and their congeners
Qiu et al. Cuprous chloride promoted coupling reaction of diethoxyphosphinyldifluoromethylcadmium reagent with aryl iodides: A practical and convenient preparation of α, α-difluoro benzylic phosphonates

Legal Events

Date Code Title Description
FB Suspension of granting procedure